BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nezastomig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nezastomig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06826768-11310@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nezastomig: Phase 1 readout est. (NCT06826768)
DESCRIPTION:Nezastomig\, phase 1\, Prostate Cancer.\nStudy: A Ph Ib Study o
 f REGN5678 Plus Cemiplimab in Patients With mCRPC\nEstimated primary compl
 etion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ne
 zastomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06826768
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03972657-11310@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT03972657)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fi
 nd Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in 
 Combination With Cemiplimab for Adult Participants With Metastatic Castrat
 ion-Resistant Prostate Cancer and Other Tumors\nEstimated primary completi
 on: 15 November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nezastomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03972657
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06085664-11310@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT06085664)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: A Pilot Presu
 rgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk\, L
 ocalized Prostate Cancer Followed by Radical Prostatectomy\nEstimated prim
 ary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nezastomig#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06085664
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125016-11310@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20300328
DTEND;VALUE=DATE:20300329
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT05125016)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fi
 nd Out if REGN4336 is Safe and How Well it Works Alone and in Combination 
 With REGN5678 for Adult Participants With Advanced Prostate Cancer\nEstima
 ted primary completion: 28 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nezastomig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05125016
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850921-11310@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20310728
DTEND;VALUE=DATE:20310729
SUMMARY:Nezastomig: Phase 1/2 readout est. (NCT07850921)
DESCRIPTION:Nezastomig\, phase 1/2\, Prostate Cancer.\nStudy: REGN21353 Alo
 ne or in Combination With Nezastomig for Metastatic Castration-Resistant P
 rostate Cancer in Adult Participants\nEstimated primary completion: 28 Jul
 y 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nezastomig#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078509
 21
URL:https://assetmemo.bio/drug/nezastomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
